Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Fund Letter | Alex GunzThe Heptagon Future Trends Fund | Novo Nordisk A/S $NVO• NYSE | PharmaceuticalsPharmaceuticals | Long NVO (Novo Nordisk A/S) DoorDash's 33.7% decline in Q1 compares to a 29.0% drop in Novo Nordisk shares – the Fund's next most notable laggard. From a contribution... | BULL | View Pitch → |
| Aug 21, 2026 | Fund Letter | Daniel GladišVltava Fund | Novo Nordisk A/S $NVO• NYSE | PharmaceuticalsPharmaceuticals | Short NVO (Novo Nordisk) We had acquired most of our position in Novo Nordisk last summer after the stock's significant year-over-year price decline was compounded by the largest single-day drop in its history. We bought the... | BEAR | View Pitch → |
| Jan 27, 2026 | Fund Letter | Michael P. McCloskeyGreensKeeper Value Fund | Novo Nordisk A/S $NVO• NYSE | PharmaceuticalsPharmaceuticals | GreensKeeper Value Fund 2025 Q4 (NVO) In our view, the market is underappreciating the durability and breadth of Novo Nordisk's GLP-1 franchise relative to the massive global obesity opportunity. This thesis was... | BULL | View Pitch → |
| Jan 27, 2026 | Fund Letter | Terry SmithFundsmith Equity Fund | Novo Nordisk A/S $NVO• NYSE | PharmaceuticalsPharmaceuticals | Fundsmith Equity Fund 2025 Q4 (NVO) Novo Nordisk managed to reaffirm my belief that you should never say 'Things can't get any worse'. The company has... | BULL | View Pitch → |
| Nov 28, 2025 | Fund Letter | Michael P. McCloskeyGreensKeeper Value Fund | Novo Nordisk A/S $NVO• NYSE | PharmaceuticalsPharmaceuticals | GreensKeeper Value Fund 2025 Q3 (NVO) Novo Nordisk (NVO) declined -19.6% in Q3 after lowering guidance due to slower obesity treatment uptake and competition from Eli Lilly's tirzepatide-based drugs. The fund remains... | BULL | View Pitch → |
| Nov 28, 2025 | Fund Letter | Mike LoebArgosy Investors | Novo Nordisk A/S $NVO• NYSE | PharmaceuticalsPharmaceuticals | Argosy Investors 2025 Q3 (NVO) Novo Nordisk (NVO) is one of two major players in the GLP-1 space, along with Eli Lilly. Novo Nordisk had... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.